Lantheus (NASDAQ:LNTH) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.360-0.410 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.370. The company issued revenue guidance of $390 million-$400 million, compared to the consensus revenue estimate of $390.55 million.Lantheus also updated its Q2 2021 guidance to 0.030-0.060 EPS.
Several research firms recently weighed in on LNTH. Zacks Investment Research cut Lantheus from a buy rating to a hold rating in a report on Wednesday. SVB Leerink lifted their target price on Lantheus from $26.00 to $31.00 and gave the stock an outperform rating in a report on Tuesday, May 4th. Finally, Credit Suisse Group upped their price target on shares of Lantheus from $17.00 to $20.00 and gave the company a neutral rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $26.25.
Lantheus stock traded up $0.96 during mid-day trading on Thursday, reaching $20.77. 1,110,362 shares of the company were exchanged, compared to its average volume of 612,555. The firm has a market cap of $1.40 billion, a PE ratio of 259.66 and a beta of 1.32. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.25 and a quick ratio of 1.79. The company has a fifty day simple moving average of $21.59 and a 200-day simple moving average of $17.14. Lantheus has a 12 month low of $10.52 and a 12 month high of $24.26.
In other news, CEO Mary Anne Heino sold 27,157 shares of Lantheus stock in a transaction on Friday, March 5th. The stock was sold at an average price of $18.26, for a total value of $495,886.82. Following the transaction, the chief executive officer now owns 711,720 shares in the company, valued at approximately $12,996,007.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul Blanchfield sold 4,061 shares of the business’s stock in a transaction on Thursday, March 4th. The stock was sold at an average price of $18.40, for a total value of $74,722.40. The disclosure for this sale can be found here. Insiders sold a total of 72,188 shares of company stock valued at $1,411,148 over the last 90 days. Corporate insiders own 2.08% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.
Featured Story: What is Depreciation?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.